Paolo Macor

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8655104/paolo-macor-publications-by-year.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	1,942 citations	22 h-index	43 g-index
65 ext. papers	2,268 ext. citations	5.6 avg, IF	4.36 L-index

#	Paper	IF	Citations
64	Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. *Blood*, **2021**, 137, 2989-2992	2.2	0
63	Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma. *Cancers*, **2021**, 13,	6.6	1
62	High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study. *World Journal of Gastroenterology*, **2021**, 27, 3130-3137	5.6	5
61	Multi-organ complement deposition in COVID-19 patients **2021**,		9
60	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. *Pharmaceutics*, **2021**, 13,	6.4	3
59	An allosteric redox switch in domain V of β-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. *Journal of Biological Chemistry*, **2021**, 297, 100890	5.4	3
58	The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis. *Frontiers in Immunology*, **2021**, 12, 693118	8.4	1
57	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. *Biomedicines*, **2021**, 9,	4.8	13
56	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *Journal of Autoimmunity*, **2021**, 124, 102728	15.5	1
55	The J-elongated conformation of β-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. *Journal of Biological Chemistry*, **2020**, 295, 10794-10806	5.4	11
54	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. *Journal of Oncology*, **2020**, 2020, 4638192	4.5	16
53	Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family. *Medicina (Lithuania)*, **2020**, 56,	3.1	
52	Complement system and phagocytosis in a colonial protochordate. *Developmental and Comparative Immunology*, **2020**, 103, 103530	3.2	7
51	Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. *International Journal of Pharmaceutics*, **2020**, 574, 118895	6.5	7
50	Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity. *Journal of Colloid and Interface Science*, **2020**, 580, 286-297	9.3	29
49	Complement Activation and Thrombin Generation by MBL Bound to β-Glycoprotein I. *Journal of Immunology*, **2020**, 205, 1385-1392	5.3	7
48	Targeting CD34 cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. *Journal of Autoimmunity*, **2019**, 103, 102288	15.5	14

47	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. *Autoimmunity Reviews*, **2019**, 18, 561-563	13.6	11
46	New advances in chronic lymphocytic leukemia treatment: Biodegradable ZnO hybrid cluster nanoparticle as antineoplastic agents **2019**, 409-430		
45	New insight into antiphospholipid syndrome: antibodies to 2glycoprotein I-domain 5 fail to induce thrombi in rats. *Haematologica*, **2019**, 104, 819-826	6.6	21
44	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. *Frontiers in Immunology*, **2018**, 9, 1388	8.4	28
43	The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties. *Journal of Shoulder and Elbow Surgery*, **2018**, 27, 1837-1844	4.3	2
42	Complement as a Biological Tool to Control Tumor Growth. *Frontiers in Immunology*, **2018**, 9, 2203	8.4	19
41	Mutations in the 3Untranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. *Haematologica*, **2017**, 102, e305-e309	6.6	11
40	Cubosomes for in vivo fluorescence lifetime imaging. *Nanotechnology*, **2017**, 28, 055102	3.4	32
39	Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot Study. *Scientific Reports*, **2017**, 7, 7544	4.9	4
38	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. *Frontiers in Immunology*, **2017**, 8, 1093	8.4	13
37	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*, **2017**, 8, 3274-3288	3.3	10
36	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. *Arthritis Research and Therapy*, **2016**, 18, 111	5.7	24
35	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. *Nano Research*, **2016**, 9, 537-548	10	10
34	Mutations at 3Untranslated Region (3WTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 306-306	2.2	
33	Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis. *Orphanet Journal of Rare Diseases*, **2016**, 11, 64	4.2	7
32	Alterations in Trabecular Bone Architecture and Cartilages in Rats with Antigen-Induced Arthritis (AIA) Resulting from Synchrotron-Based X-Ray Imaging Analysis. *IFMBE Proceedings*, **2016**, 409-413	0.2	1
31	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. *Blood*, **2016**, 127, 365-7	2.2	51
30	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. *Journal of Immunology*, **2015**, 195, 5602-7	5.3	28

29	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. *International Journal of Nanomedicine*, **2015**, 10, 4099-109	7.3	21
28	Targeted Nanoparticles for the Delivery of Antagomir17: New Approach for the Treatment of Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 5293-5293	2.2	
27	Phage display technology for human monoclonal antibodies. *Methods in Molecular Biology*, **2014**, 1060, 277-95	1.4	13
26	A non-complement-fixing antibody to β glycoprotein I as a novel therapy for antiphospholipid syndrome. *Blood*, **2014**, 123, 3478-87	2.2	98
25	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. *Blood*, **2014**, 124, 1715-26	2.2	220
24	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. *Journal of Hematology and Oncology*, **2014**, 7, 79	22.4	11
23	New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. *PLoS ONE*, **2013**, 8, e74216	3.7	27
22	Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. *PLoS ONE*, **2013**, 8, e58696	3.7	22
21	Simple scale-up of recombinant antibody production using an UCOE containing vector. *New Biotechnology*, **2012**, 29, 477-84	6.4	35
20	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. *Arthritis and Rheumatism*, **2012**, 64, 2559-67		37
19	New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles. *Blood*, **2012**, 120, 158-158	2.2	
18	The development of atypical hemolytic uremic syndrome depends on complement C5. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 137-45	12.7	89
17	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. *Expert Opinion on Biological Therapy*, **2010**, 10, 863-73	5.4	14
16	Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. *Current Clinical Pharmacology*, **2010**, 5, 246-50	2.5	5
15	Complement in human diseases: Lessons from complement deficiencies. *Molecular Immunology*, **2009**, 46, 2774-83	4.3	216
14	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. *Blood*, **2009**, 113, 3640-8	2.2	38
13	An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. *Current Pharmaceutical Design*, **2008**, 14, 2023-39	3.3	17
12	Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. *Transplantation*, **2008**, 86, 1445-51	1.8	22

List of Publications

11	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. *Molecular Imaging*, **2008**, 7, 7290.2008.00028	3.7	23
10	In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. *Molecular Imaging*, **2008**, 7, 272-82	3.7	13
9	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. *Arthritis and Rheumatism*, **2007**, 56, 1187-97		27
8	Complement as effector system in cancer immunotherapy. *Immunology Letters*, **2007**, 111, 6-13	4.1	60
7	In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. *Cancer Research*, **2007**, 67, 10556-63	10.1	131
6	Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. *Cancer Research*, **2006**, 66, 3876-83	10.1	31
5	Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. *Blood*, **2005**, 106, 2340-6	2.2	256
4	Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. *European Journal of Immunology*, **2005**, 35, 2175-83	6.1	79
3	The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. *European Journal of Immunology*, **2002**, 32, 2773-82	6.1	37
2	The complement system at the feto-maternal interface: friend or foe?. *American Journal of Reproductive Immunology*, **2002**, 48, 142-143	3.8	
1	Complement Component 3 expressed by the endometrial ectopic tissue is involved in the endometriotic lesion formation through mast cell activation		1